

Eric J Feuer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9499722/publications.pdf>

Version: 2024-02-01

66
papers

17,332
citations

93792

39
h-index

124990

64
g-index

68
all docs

68
docs citations

68
times ranked

21198
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of Joint Lung Cancer Screening and Cessation Interventions Under the New Recommendations of the U.S. Preventive Services Task Force. <i>Journal of Thoracic Oncology</i> , 2022, 17, 160-166.	0.5	20
2	Estimating life expectancy adjusted by self-rated health status in the United States: national health interview survey linked to the mortality. <i>BMC Public Health</i> , 2022, 22, 141.	1.2	9
3	Evaluation of the Benefits and Harms of Lung Cancer Screening With Low-Dose Computed Tomography. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 988.	3.8	181
4	Updated Methodology for Projecting U.S.- and State-Level Cancer Counts for the Current Calendar Year: Part I: Spatio-temporal Modeling for Cancer Incidence. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 1620-1626.	1.1	6
5	Characterizing Trends in Cancer Patients' Survival Using the JPSurv Software. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 2001-2009.	1.1	9
6	Updated Methodology for Projecting U.S.- and State-Level Cancer Counts for the Current Calendar Year: Part II: Evaluation of Incidence and Mortality Projection Methods. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 1993-2000.	1.1	9
7	Expected Monetary Impact of Oncotype DX Score-Concordant Systemic Breast Cancer Therapy Based on the TAILORx Trial. <i>Journal of the National Cancer Institute</i> , 2020, 112, 154-160.	3.0	27
8	A Comparative Modeling Analysis of Risk-Based Lung Cancer Screening Strategies. <i>Journal of the National Cancer Institute</i> , 2020, 112, 466-479.	3.0	67
9	The Effect of Advances in Lung-Cancer Treatment on Population Mortality. <i>New England Journal of Medicine</i> , 2020, 383, 640-649.	13.9	893
10	Disparities of National Lung Cancer Screening Guidelines in the US Population. <i>Journal of the National Cancer Institute</i> , 2020, 112, 1136-1142.	3.0	48
11	Small Area Estimation of Cancer Risk Factors and Screening Behaviors in US Counties by Combining Two Large National Health Surveys. <i>Preventing Chronic Disease</i> , 2019, 16, E119.	1.7	12
12	Annual Report to the Nation on the Status of Cancer, Featuring Cancer in Men and Women Age 20-49 Years. <i>Journal of the National Cancer Institute</i> , 2019, 111, 1279-1297.	3.0	219
13	Using Patient Preferences to Determine Noninferiority Margins in Trials. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 2137.	3.8	0
14	Evidence-based sizing of non-inferiority trials using decision models. <i>BMC Medical Research Methodology</i> , 2019, 19, 3.	1.4	6
15	Projecting the effects of tobacco control policies in the USA through microsimulation: a study protocol. <i>BMJ Open</i> , 2018, 8, e019169.	0.8	31
16	Variance Estimation and Confidence Intervals for 11 Commonly Used Health Disparity Measures. <i>JCO Clinical Cancer Informatics</i> , 2018, 2, 1-19.	1.0	10
17	Smoking and Lung Cancer Mortality in the United States From 2015 to 2065. <i>Annals of Internal Medicine</i> , 2018, 169, 684.	2.0	150
18	Effects of Radiotherapy in Early-Stage, Low-Recurrence Risk, Hormone-Sensitive Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2018, 110, 1370-1379.	3.0	31

#	ARTICLE	IF	CITATIONS
19	Annual Report to the Nation on the Status of Cancer, part II: Recent changes in prostate cancer trends and disease characteristics. <i>Cancer</i> , 2018, 124, 2801-2814.	2.0	200
20	The impact of overdiagnosis on the selection of efficient lung cancer screening strategies. <i>International Journal of Cancer</i> , 2017, 140, 2436-2443.	2.3	36
21	Annual Report to the Nation on the Status of Cancer, 1975–2014, Featuring Survival. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	1,135
22	Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials. <i>Annals of Internal Medicine</i> , 2017, 167, 449.	2.0	160
23	Urban/Rural Differences in Breast and Cervical Cancer Incidence: The Mediating Roles of Socioeconomic Status and Provider Density. <i>Women's Health Issues</i> , 2017, 27, 683-691.	0.9	64
24	Risk prediction models for selection of lung cancer screening candidates: A retrospective validation study. <i>PLoS Medicine</i> , 2017, 14, e1002277.	3.9	216
25	Development, Feasibility, and Small-Scale Implementation of a Web-Based Prognostic Tool—Surveillance, Epidemiology, and End Results Cancer Survival Calculator. <i>JMIR Cancer</i> , 2017, 3, e9.	0.9	10
26	Health-Care Utilization by Prognosis Profile in a Managed Care Setting: Using the Surveillance, Epidemiology and End Results Cancer Survival Calculator SEER*CSC. <i>Journal of the National Cancer Institute Monographs</i> , 2014, 2014, 275-281.	0.9	5
27	Comparative analysis of 5 lung cancer natural history and screening models that reproduce outcomes of the NLST and PLCO trials. <i>Cancer</i> , 2014, 120, 1713-1724.	2.0	65
28	The Surveillance, Epidemiology, and End Results Cancer Survival Calculator SEER*CSC: Validation in a Managed Care Setting. <i>Journal of the National Cancer Institute Monographs</i> , 2014, 2014, 265-274.	0.9	17
29	Exploring the Recent Trend in Esophageal Adenocarcinoma Incidence and Mortality Using Comparative Simulation Modeling. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 997-1006.	1.1	61
30	Patterns of Birth Cohort–Specific Smoking Histories, 1965–2009. <i>American Journal of Preventive Medicine</i> , 2014, 46, e31-e37.	1.6	150
31	Personalizing Age of Cancer Screening Cessation Based on Comorbid Conditions: Model Estimates of Harms and Benefits. <i>Annals of Internal Medicine</i> , 2014, 161, 104.	2.0	123
32	Benefits and Harms of Computed Tomography Lung Cancer Screening Strategies: A Comparative Modeling Study for the U.S. Preventive Services Task Force. <i>Annals of Internal Medicine</i> , 2014, 160, 311.	2.0	377
33	Life tables adjusted for comorbidity more accurately estimate noncancer survival for recently diagnosed cancer patients. <i>Journal of Clinical Epidemiology</i> , 2013, 66, 1376-1385.	2.4	52
34	Assessing Non–Cancer-Related Health Status of US Cancer Patients: Other-Cause Survival and Comorbidity Prevalence. <i>American Journal of Epidemiology</i> , 2013, 178, 339-349.	1.6	120
35	Impact of Reduced Tobacco Smoking on Lung Cancer Mortality in the United States During 1975–2000. <i>Journal of the National Cancer Institute</i> , 2012, 104, 541-548.	3.0	145
36	Chapter 3: Cohort Life Tables by Smoking Status, Removing Lung Cancer as a Cause of Death. <i>Risk Analysis</i> , 2012, 32, S25-38.	1.5	44

#	ARTICLE	IF	CITATIONS
37	<i>Chapter 2</i>: Birthâ€Cohortâ€Specific Estimates of Smoking Behaviors for the U.S. Population. Risk Analysis, 2012, 32, S14-24.	1.5	61
38	<i>Chapter 1</i>: The Impact of the Reduction in Tobacco Smoking on U.S. Lung Cancer Mortality, 1975â€2000: An Introduction to the Problem. Risk Analysis, 2012, 32, S6-S13.	1.5	15
39	The Cancer Survival Query System: Making survival estimates from the Surveillance, Epidemiology, and End Results program more timely and relevant for recently diagnosed patients. Cancer, 2012, 118, 5652-5662.	2.0	32
40	Predicting USâ€and stateâ€level cancer counts for the current calendar year. Cancer, 2012, 118, 1091-1099.	2.0	44
41	Predicting USâ€and stateâ€level cancer counts for the current calendar year. Cancer, 2012, 118, 1100-1109.	2.0	48
42	Dynamic Microsimulation Models for Health Outcomes. Medical Decision Making, 2011, 31, 10-18.	1.2	144
43	Productivity Savings from Colorectal Cancer Prevention and Control Strategies. American Journal of Preventive Medicine, 2011, 41, e5-e14.	1.6	28
44	Projections of the Cost of Cancer Care in the United States: 2010-2020. Journal of the National Cancer Institute, 2011, 103, 117-128.	3.0	2,151
45	Estimating average annual per cent change in trend analysis. Statistics in Medicine, 2009, 28, 3670-3682.	0.8	629
46	Modelling Population-Based Cancer Survival Trends by using Join Point Models for Grouped Survival Data. Journal of the Royal Statistical Society Series A: Statistics in Society, 2009, 172, 405-425.	0.6	21
47	Weighted Normal Spatial Scan Statistic for Heterogeneous Population Data. Journal of the American Statistical Association, 2009, 104, 886-898.	1.8	55
48	Effects of Mammography Screening Under Different Screening Schedules: Model Estimates of Potential Benefits and Harms. Annals of Internal Medicine, 2009, 151, 738.	2.0	509
49	Productivity Costs of Cancer Mortality in the United States: 2000â€2020. Journal of the National Cancer Institute, 2008, 100, 1763-1770.	3.0	212
50	Combining Information From Two Surveys to Estimate County-Level Prevalence Rates of Cancer Risk Factors and Screening. Journal of the American Statistical Association, 2007, 102, 474-486.	1.8	96
51	Reconstructing PSA testing patterns between black and white men in the US from Medicare claims and the National Health Interview Survey. Cancer, 2007, 109, 1877-1886.	2.0	81
52	A New Method of Estimating United States and State-level Cancer Incidence Counts for the Current Calendar Year. Ca-A Cancer Journal for Clinicians, 2007, 57, 30-42.	157.7	86
53	Chapter 1: Modeling the Impact of Adjuvant Therapy and Screening Mammography on U.S. Breast Cancer Mortality Between 1975 and 2000: Introduction to the Problem. Journal of the National Cancer Institute Monographs, 2006, 2006, 2-6.	0.9	26
54	Chapter 15: Impact of Adjuvant Therapy and Mammography on U.S. Mortality From 1975 to 2000: Comparison of Mortality Results From the CISNET Breast Cancer Base Case Analysis. Journal of the National Cancer Institute Monographs, 2006, 2006, 112-121.	0.9	59

#	ARTICLE	IF	CITATIONS
55	Geographic association between mammography use and mortality reduction in the US. <i>Cancer Causes and Control</i> , 2005, 16, 691-699.	0.8	20
56	The use of modeling to understand the impact of screening on US mortality: examples from mammography and PSA testing. <i>Statistical Methods in Medical Research</i> , 2004, 13, 421-442.	0.7	39
57	An Ecologic Study of Prostate-specific Antigen Screening and Prostate Cancer Mortality in Nine Geographic Areas of the United States. <i>American Journal of Epidemiology</i> , 2004, 160, 1059-1069.	1.6	36
58	A New Method of Predicting US and State-Level Cancer Mortality Counts for the Current Calendar Year. <i>Ca-A Cancer Journal for Clinicians</i> , 2004, 54, 30-40.	157.7	56
59	Cancer Statistics, 2004. <i>Ca-A Cancer Journal for Clinicians</i> , 2004, 54, 8-29.	157.7	3,622
60	Trends in Use of Adjuvant Multi-Agent Chemotherapy and Tamoxifen for Breast Cancer in the United States: 1975-1999. <i>Journal of the National Cancer Institute</i> , 2002, 94, 1626-1634.	3.0	126
61	Modeling the impact of the decline in distant stage disease on prostate carcinoma mortality rates. <i>Cancer</i> , 2002, 95, 870-880.	2.0	32
62	Permutation tests for joinpoint regression with applications to cancer rates. , 2000, 19, 335-351.		3,877
63	Does Size Matter? Association Between Number of Patients Treated and Patient Outcome in Metastatic Testicular Cancer. <i>Journal of the National Cancer Institute</i> , 1999, 91, 816-818.	3.0	42
64	Cancer Surveillance Series: Interpreting Trends in Prostate Cancer—Part II: Cause of Death Misclassification and the Recent Rise and Fall in Prostate Cancer Mortality. <i>Journal of the National Cancer Institute</i> , 1999, 91, 1025-1032.	3.0	211
65	The role of prostate-specific antigen (PSA) testing patterns in the recent prostate cancer incidence decline in the United States. <i>Cancer Causes and Control</i> , 1998, 9, 519-527.	0.8	131
66	How Much of the Recent Rise in Breast Cancer Incidence Can Be Explained by Increases in Mammography Utilization?. <i>American Journal of Epidemiology</i> , 1992, 136, 1423-1436.	1.6	131